UPM is entering the exciting world of 3D printing, offering novel non-animal derived, ready-to-use hydrogels which mimic the in vivo environment to support cell growth and differentiation. The new GrowInk™ Bioinks product range is being launched at SLAS2020, and is ideal for a wide range of bioprinting applications, including cell encapsulation and scaffold preparation for tissue engineering, drug discovery and regenerative medicine.
The two main components of GrowInk Bioinks – nanofibrillar cellulose and water – provide a fully defined matrix that can be mixed directly with cells and customised with additional growth factors or adhesion proteins. Compatible with a large variety of 3D printers, GrowInk Bioinks have been developed to provide exceptional imaging quality, presenting the opportunity to revolutionise research in this area.
UPM’s GrowDex® product range is also expanding, with a new sterile hydrogel – GrowDex-A – containing avidin-conjugated nanofibrillar cellulose. The product has been specifically developed to bind biotinylated molecules including proteins, peptides and antibiotics, and is suitable for use in various applications, such as spheroid formation for 3D cell culture.
To learn more about UPM’s latest advancements, visit booth #238 at SLAS2020.
For further information please contact:
Jane Spencer-Fry, Director, UPM Biomedicals, tel. +44 7881 557511
Kari Luukko, Director, Quality management and regulatory affairs, UPM Biomedicals, tel. +358 400 259 866
We deliver renewable and responsible solutions and innovate for a future beyond fossils across six business areas: UPM Biorefining, UPM Energy, UPM Raflatac, UPM Specialty Papers, UPM Communication Papers and UPM Plywood. We employ around 19,000 people worldwide and our annual sales are approximately EUR 10.5 billion. Our shares are listed on Nasdaq Helsinki Ltd.
UPM Biofore - Beyond fossils. www.upm.com